The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by RBC Capital on January 14, 2025. The analyst firm set a price target for $45.00 expecting DYN to rise to within 12 months (a possible 220.28% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for Dyne Therapeutics (NASDAQ:DYN) was provided by RBC Capital, and Dyne Therapeutics reiterated their outperform rating.

The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.

The last downgrade for Dyne Therapeutics Inc happened on October 24, 2024 when JP Morgan changed their price target from $43 to $35 for Dyne Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.

While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a reiterated with a price target of $45.00 to $45.00. The current price Dyne Therapeutics (DYN) is trading at is $14.05, which is out of the analyst’s predicted range.